Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,770 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.
Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Naito S, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Uno S, Akaza H. Uemura H, et al. Among authors: kobayashi k. BJUI Compass. 2021 Aug 20;3(1):26-36. doi: 10.1002/bco2.103. eCollection 2022 Jan. BJUI Compass. 2021. PMID: 35475157 Free PMC article.
Androgen deprivation therapy prevents bladder cancer recurrence.
Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H. Izumi K, et al. Among authors: kobayashi k. Oncotarget. 2014 Dec 30;5(24):12665-74. doi: 10.18632/oncotarget.2851. Oncotarget. 2014. PMID: 25557268 Free PMC article.
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H, Kondo K, Kawahara T, Kaneta T, Tateishi U, Ueno D, Namura K, Kobayashi K, Miyoshi Y, Yumura Y, Makiyama K, Hayashi N, Hasumi H, Osaka K, Yokomizo Y, Teranishi JI, Hattori Y, Inoue T, Uemura H, Yao M, Nakaigawa N. Ito H, et al. Among authors: kobayashi k. Cancer Chemother Pharmacol. 2017 May;79(5):855-861. doi: 10.1007/s00280-017-3275-z. Epub 2017 Mar 22. Cancer Chemother Pharmacol. 2017. PMID: 28331985
A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.
Kasahara R, Kawahara T, Ohtake S, Saitoh Y, Tsutsumi S, Teranishi JI, Miyoshi Y, Nakaigawa N, Yao M, Kobayashi K, Uemura H. Kasahara R, et al. Among authors: kobayashi k. Biomed Res Int. 2017;2017:7981549. doi: 10.1155/2017/7981549. Epub 2017 Apr 13. Biomed Res Int. 2017. PMID: 28497065 Free PMC article. Clinical Trial.
Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy.
Uemura K, Kawahara T, Yamashita D, Jikuya R, Abe K, Tatenuma T, Yokomizo Y, Izumi K, Teranishi JI, Makiyama K, Yumura Y, Kishida T, Udagawa K, Kobayashi K, Miyoshi Y, Yao M, Uemura H. Uemura K, et al. Among authors: kobayashi k. Biomed Res Int. 2017;2017:7538647. doi: 10.1155/2017/7538647. Epub 2017 Aug 29. Biomed Res Int. 2017. PMID: 28948170 Free PMC article.
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N, Kondo K, Kaneta T, Tateishi U, Minamimoto R, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Hayashi N, Osaka K, Muraoka K, Izumi K, Kawahara T, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Inoue T, Yao M. Nakaigawa N, et al. Among authors: kobayashi k. Cancer Chemother Pharmacol. 2018 Apr;81(4):739-744. doi: 10.1007/s00280-018-3542-7. Epub 2018 Feb 20. Cancer Chemother Pharmacol. 2018. PMID: 29464355
11,770 results
You have reached the last available page of results. Please see the User Guide for more information.